HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

HIMS

Hims & Hers Health, Inc. (Russell 2000)

Healthcare — Drug Manufacturers - Specialty & Generic

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Hold 2.8 / 5 13 analysts
$29.32
$-0.92 (-3.04%)
Target: $29.77 (1.5%)
Sign in to add HIMS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$6.79B
P/E Ratio (TTM)-
Forward P/E22.47
EPS (TTM)$-0.09
Dividend Yield-
Profit Margin-0.56%
Revenue Growth3.80%
ROE-2.66%
Debt/Equity253.73
Recommendation Hold 2.8
Analyst Target$29.77
Analysts13
Indexes Russell 2000

Technical Indicators

RSI (14)32.1
Beta2.34
SMA 20$34.01
SMA 40$32.12
52-Week High$70.43
52-Week Low$13.74
50-Day Avg$30.42
200-Day Avg$30.92
Avg Volume$19.00M
Volume$11.63M

Performance Analysis

NEUTRAL

HIMS presents a mixed picture with both positive and negative indicators.

~ Trading at 27% of its 52-week range.
~ RSI at 32.1 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 3.8% year-over-year.
- Operating at a loss with -0.6% margin.
~ Wall Street consensus is "Hold" from 13 analysts.
+ Average analyst target of $29.77 implies 1.5% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report